Novel therapies for rheumatoid arthritis

Expert Opinion on Investigational Drugs

Volumn 15, Issue 11, 2006, Pages 1427-1441

  Tremouler, Adriana H ^a   Albani, Salvatore ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apratastat; Biological therapies; DMARDs; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ADENOSINE A3 RECEPTOR AGONIST; ADENOVIRUS VECTOR; ANTIRHEUMATIC AGENT; APRATASTAT; ATLIZUMAB; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CHEMOKINE; COLLAGEN TYPE 2; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; HEAT SHOCK PROTEIN; I KAPPA B; INCB 3284; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 8 RECEPTOR ANTAGONIST; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MLN 1202; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; RITUXIMAB; TGN 1412; TMI 2; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; TUMOR NECROSIS FACTOR ALPHA MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; IMMUNOSUPPRESSIVE AGENT; NEW DRUG;

ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; BIOLOGICAL THERAPY; BONE DESTRUCTION; CARTILAGE DEGENERATION; CLINICAL TRIAL; CYTOKINE RELEASE; DOSE RESPONSE; DRUG APPROVAL; ENZYME INHIBITION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LEUKOPENIA; METABOLIC INHIBITION; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; SYNOVITIS; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; LEUKOCYTE; OSTEOCLAST;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; CHEMOKINES; CLINICAL TRIALS; CYTOKINES; DRUGS, INVESTIGATIONAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES; OSTEOCLASTS; SIGNAL TRANSDUCTION;

EID: 33750119197     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.11.1427     Document Type: Review

References (156)

1. WOLFE AM: The epidemiology of rheumatoid arthritis: a review. I. Surveys. Bull. Rheum. Dis. (1968) 19(2):518-523.
2. HOCHBERG MC, SPECTOR TD: Epidemiology of rheumatoid arthritis: update. Epidemiol. Rev. (1990) 12:247-252.
3. HARRIS ED Jr: Rheumatoid arthritis. Pathophysiology and implications for therapy. N. Engl. J. Med. (1990) 322(18):1277-1289.
4. The burden of musculoskeletal conditions at the start of the new millennium. World Health Organ Tech. Rep. Ser. (2003) 919:i-x.
5. WONG JB, RAMEY DR, SINGH G: Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum. (2001) 44(12):2746-2749.
6. YELIN E, WANKE LA: An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum. (1999) 42(6):1209-1218.
7. OLLIER W, THOMSON W: Population genetics of rheumatoid arthritis. Rheum. Dis. Clin. North Am. (1992) 18(4):741-759.
8. CHOY EH, PANAYI GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. (2001) 344(12):907-916.
9. TAK PP, BRESNIHAN B: The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum. (2000) 43(12):2619-2633.
10. GORONZY JJ, WEYAND CM: T-cell regulation in rheumatoid arthritis. Curr. Opin. Rheumatol. (2004) 16(3):212-217.
11. FIRESTEIN GS, ZVAIFLER NJ: How important are T cells in chronic rheumatoid synovitis? II. T cell-independent mechanisms from beginning to end. Arthritis Rheum. (2002) 46(2):298-308.
12. SZEKANECZ Z, KOCH AE: Chemokines mid angiogenesis. Curr. Opin. Rheumatol. (2001) 13(3):202-208.
13. PANAYI GS, CORRIGALL VM, PITZALIS C: Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. Rheum. Dis. Clin. North Am. (2001) 27(2):317-334.
14. ZHANG Z, BRIDGES SL Jr: Pathogenesis of rheumatoid arthritis. Role of B lymphocytes. Rheum. Dis. Clin. North Am. (2001) 27(2):335-353.
15. YAMANISHI Y, FIRESTEIN GS: Pathogenesis of rheumatoid arthritis: the role of synoviocytes. Rheum. Dis. Clin. North Am. (2001) 27(2):355-371.
16. KOCH AE, KUNKEL SL, HARLOW LA et al.: Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J. Clin. Invest. (1992) 90(3):772-779.
17. SZEKANECZ Z, SZUCS G, SZANTO S, KOCH AE: Chemokines in rheumatic diseases. Curr. Drug Targets (2006) 7(1):91-102.
18. SZEKANECZ Z, KIM J, KOCH AE: Chemokines and chemokine receptors in rheumatoid arthritis. Semin. Immunol. (2003) 15(1):15-21.
19. TAKAHASHI Y, KASAHARA T, SAWAI T et al.: The participation of IL-8 in the synovial lesions at an early stage of rheumatoid arthritis. Tohoku J. Exp. Med. (1999) 188(1):75-87.
20. NISHIMURA A, AKAHOSHI T, TAKAHASHI M et al.: Attenuation of monosodium urate crystal-induced arthritis in rabbits by a neutralizing antibody against interleukin-8. J. Leukoc. Biol. (1997) 62(4):444-449.
21. MATSUKAWA A, YOSHIMURA T, FUJIWARA K, MAEDA T, OHKAWARA S, YOSHINAGA M: Involvement of growth-related protein in lipopolysaccharide-induced rabbit arthritis: cooperation between growth-related protein and IL-8, and interrelated regulation among TNFα, IL-1, IL-1 receptor antagonist, IL-8, and growth-retated protein. Lab. Invest. (1999) 79(5):591-600.
22. PODOLIN PL, BOLOGNESE BJ, FOLEY JJ et al.: A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J. Immunol. (2002) 169(11):6435-6444.
23. HALLORAN MM, WOODS JM, STRIETER RM et al.: The role of an epithelial neutrophil-activating peptide-78-like protein in rat adjuvant-induced arthritis. J. Immunol. (1999) 162(12):7492-7500.
24. KOCH AE, KUNKEL SL, SHAH MR et al.: Growth-related gene product α. A chemotactic cytokine for neutrophils in rheumatoid arthritis. J. Immunol. (1995) 155(7):3660-3666.
25. NANKI T, URASAKI Y, IMAI T et al.: Inhibition of fractalkine ameliorates murine collagen-induced arthritis. J. Immunol. (2004) 173(11):7010-7016.
26. KATRIB A, TAK PP, BERTOUCH JV et al.: Expression of chemokines and matrix metalloproteinases in early rheumatoid arthritis. Rbeumatology (2001) 40(9):988-994.
27. LIU SH, WONG CS, CHANG DM: Increased monocyte chemoattractant protein-1 in knee joints of rats with adjuvant-induced arthritis: in vivo microdialysis. J. Rheumatol. (2005) 32(11):2205-2211.
28. HARINGMAN JJ, SMEETS TJ, REINDERS-BLANKERT P, TAK PP: Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann. Rheum. Dis. (2006) 65(3):294-300.
29. HAAS CS, MARTINEZ RJ, ATTIA N, HAINES GK III, CAMPBELL PL, KOCH AE: Chemokine receptor expression in rat adjuvant-induced arthritis. Arthritis Rheum. (2005) 52(12):3718-3730.
30. STANCZYK J, KOWALSKI ML, GRZEGORCZYK J et al.: RANTES and chemotactic activity in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Mediators Inflamm. (2005) 2005(6):343-348.
31. KASAMA T, STRIETER RM, LUKACS NW, LINCOLN PM, BURDICK MD, KUNKEL SL: Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis. J. Clin. Invest. (1995) 95(6):2868-2876.
32. OGATA H, TAKEYA M, YOSHIMURA T, TAKAGI K, TAKAHASHI K: The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J. Pathol. (1997) 182(1):106-114.
33. BARNES DA, TSE J, KAUTHOLD M et al.: Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J. Clin. Invest. (1998) 101(12):2910-2919.
34. HARINGMAN JJ, GERLAG DM, SMEETS TJ et al.: A randomized placebo controlled trial with an anti-MCP-1 (CCL2) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. (2004) 50(Suppl.):S238.
35. KATSCHKE KJ Jr, ROTTMAN JB, RUTH JH et al.: Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum. (2001) 44(5):1022-1032.
36. BRUHL H, WAGNER K, KELLNER H, SCHATTENKIRCHNER M, SCHLONDORFF D, MACK M: Surface expression of CC- and CXC-chemokine receptors on leucocyte subsets in inflammatory joint diseases. Clin. Exp. Immunol. (2001) 126(3):551-559.
37. MACK M, BRUHL H, GRUBER R et al.: Predominance of mononuclear cells expressing the chemokine receptor CCR5 in synovial effusions of patients with different forms of arthritis. Arthritis Rheum. (1999) 42(5):981-988.
38. + T cells. J. Immunol. (2004) 172(2):890-898.
39. QUINONES MP, AHUJA SK, JIMENEZ F et al.: Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J. Clin. Invest. (2004) 113(6):856-866.
40. SHAHRARA S, PROUDFOOT AE, WOODS JM et al.: Amelioration of rat adjuvant-induced arthritis by Met-RANTES. Arthritis Rheum. (2005) 52(6):1907-1919.
41. PRAHALAD S: Negative association between the chemokine receptor CCR5-Δ32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun. (2006) 7(3):264-268.
42. SHAHRARA S, AMIN MA, WOODS JM, HAINES GK, KOCH AE: Chemokine receptor expression and in vivo signaling pathways in the joints of rats with adjuvant-induced arthritis. Arthritis Rheum. (2003) 48(12):3568-3583.
43. GLADUE RP, COLE SH, ROACH ML et al.: The human specific CCRI antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCRI transgenic mice. J. Immunol. (2006) 176(5):3141-3148.
44. HARINGMAN JJ, KRAAN MC, SMEETS TJ, ZWINDERMAN KH, TAK PP: Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62(8):715-721.
45. ISOMAKI P, PUNNONEN J: Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Ann. Med. (1997) 29(6):499-507.
46. KAY J, CALABRESE L: The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology (2004) 43(Suppl. 3):iii2-iii9.
47. SMEETS TJ, BARG EC, KRAAN MC, SMITH MD, BREEDVELD FC, TAK PP: Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62(7):635-638.
48. ST CLAIR EW, VAN DER HEIJDE DM, SMOLEN JS et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. (2004) 50(11):3432-3443.
49. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. (2003) 48(1):35-45.
50. KLARESKOG L, VAN DER HD, DE JAGER JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet (2004) 363 (9410):675-681.
51. GOMEZ-REINO JJ, CARMONA L, VALVERDE VR, MOLA EM, MONTERO MD: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. (2003) 48(8):2122-2127.
52. Tuberculosis associated with blocking agents against tumor necrosis factor-α - California, 2002 - 2003. MMWR Morb. Mortal. Wkly Rep. (2004) 53(30):683-686.
53. BROWN SL, GREENE MH, GERSHON SK, EDWARDS ET BRAUN MM: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. (2002) 46(12):3151-3158.
54. LISTING J, STRANGFELD A, KARY S et al.: Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. (2005) 52(11):3403-3412.
55. WALLIS RS, BRODER MS, WONG JY, HANSON ME, BEENHOUWER DO: Granulomarous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. (2004) 38(9):1261-1265.
56. WOLFE F, MICHAUD K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. (2004) 50(6):1740-1751.
57. SOLAU-GERVAIS E, LAXENAIRE N, CORTET B, DUBUCQUOI S, DUQUESNOY B, FLIPO RM: Lack of efficacy of a third tumour necrosis factor a antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology (2006) 45(9):1121-1124.
58. LE GT ABBENANTE G: Inhibitors of TACE and caspase-1 as anti-inflammatory drugs. Curr. Med. Chem. (2005) 12(25):2963-2977.
59. ZHANG Y, HEGEN M, XU J et al.: Characterization of (2R, 3S)-2-( 4-(2-burynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-α converting enzyme. Int. Immunopharmacol. (2004) 4(14):1845-1857.
60. KIMURA N, NOJIMA T, SATO S et al.: Long-term efficacy and safety of bucillamine in patients with rheumatoid arthritis: 5-year study. Program and abstracts of EULAR 2006. 7th Annual European Congress of Rheumatology. Amsterdam, The Netherlands (21 - 24 June 2006) (Abstract AB0209).
61. HORAI R, SAIJO S, TANIOKA H et al.: Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. (2000) 191(2):313-320.
62. COHEN S, HURD E, CUSH J et al.: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46(3):614-624.
63. FLEISCHMANN RM, TESSER J, SCHIFF M et al.: Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2006) 65(8):1006-1012.
64. ECONOMIDES AN, CARPENTER LR, RUDGE JS et al.: Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. (2003) 9(1):47-52.
65. HATA H, SAKAGUCHI N, YOSHITOMI H et al.: Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J. Clin. Invest. (2004) 114(4):582-588.
66. MADHOK R, CRILLY A, WATSON J, CAPELL HA: Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann. Rheum. Dis. (1993) 52(3):232-234.
67. NISHIMOTO N, YOSHIZAKI K, MIYASAKA N et al.: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. (2004) 50(6):1761-1769.
68. WOO P, WILKINSON N, PRIEUR AM et al.: Open label Phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle ofthe efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res. Ther. (2005) 7(6):R1281-R1288.
69. ROCHE HOLDING AG: Actemra (tocilizumab) monotherapy significantly slows down damage to joints in patients with early aggressive rheumatoid arthritits. Am. Coll. Rheumatol. (2005) (Press Release).
70. BASLUND B, TVEDE N, DANNESKIOLD-SAMSOE B et al.: Targeting interieukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum. (2005) 52(9):2686-2692.
71. PLATER-ZYBERK C, JOOSTEN LA, HELSEN MM et al.: Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J. Clin. Invest. (2001) 108(12):1825-1832.
72. HAMASAKI T, HASHIGUCHI S, ITO Y et al.: Human anti-human IL-18 antibody recognizing the IL-18-binding site 3 with IL-18 signaling blocking activity. J. Biochem. (2005) 138(4):433-442.
73. TANAKA Y. The role of chemokines and adhesion molecules in the pathogenesis of rheumatoid arthritis. Drugs Today (2001) 37(7):477-484.
74. KAVANAUGH AF, DAVIS LS, NICHOLS LA et al.: Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. (1994) 37(7):992-999.
75. KAVANAUGH AF, DAVIS LS, JAIN RI, NICHOLS LA, NORRIS SH, LIPSKY PE: A Phase I/lI open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J. Rheumatol. (1996) 23(8):1338-1344.
76. KAVANAUGH AF, SCHULZE-KOOPS H, DAVIS LS, LIPSKY PE: Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum. (1997) 40(5):849-853.
77. CARTER RA, CAMPBELL IK, O'DONNEL KL, WICKS IP: Vascular cell adhesion molecule-1 (VCAM-1) blockade in collagen-induced arthritis reduces joint involvement and alters B cell trafficking. Clin. Exp. Immunol. (2002) 128(1):44-51.
78. WONG MX, HAYBALL JD, HOGARTH PM, JACKSON DE: The inhibitory co-receptor, PECAM-1 provides a protective effect in suppression of collagen-induced arthritis. J. Clin. Immunol. (2005) 25(1):19-28.
79. ILANGUMARAN S, BORISCH B, HOESSLI DC: Signal transduction via CD44: role of plasma membrane microdomains. Leuk. Lymphoma (1999) 35(5-6):455-469.
80. MIKECZ K, BRENNAN FR, KIM JH, GLANT TT. Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis. Nat. Med. (1995) 1(6):558-563.
81. 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann. Rheum. Dis. (2002) 61(Suppl. 2):ii96-ii99.
82. OLSEN NJ, BROOKS RH, CUSH JJ et al.: A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. Arthritis Rheum. (1996) 39(7):1102-1108.
83. TAKEMURA S, KLIMIUK PA, BRAUN A, GORONZY JJ, WEYAND CM: T cell activation in rheumatoid synovium is B cell dependent. J. Immunol. (2001) 167(8):4710-4718.
84. EDWARDS JC, SZCZEPANSKI L, SZECHINSKI J et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. (2004) 350(25):2572-2581.
85. HIGASHIDA J, WUN T, SCHMIDT S, NAGUWA SM, TUSCANO JM: Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-α treatment. J. Rheumatol. (2005) 32(11):2109-2115.
86. EDWARDS J, LEANDRO M, CAMBRIDGE G: Repeated B lymphocyte depletion therapy in rheumatoid arthritis: 5 year follow-up. Am. Coll. Rheumatol. (2006) (Abstract 270).
87. STOHL W, CHATHAM W, WEISSMAN M et al.: Belimumab (BmAb), a novel fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), selectively modulates B-cell subpopulations and immunoglobulins in a heterogeneous rheumatoid arthritis subject population. Am. Coll. Rheumatol. (2006) (Abstract 1160).
88. KLARESKOG L, FORSUM U, SCHEYNIUS A, KABELITZ D, WIGZELL H: Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis. Proc. Nod. Acad. Sci. USA (1982) 79(11):3632-3636.
89. MIMA T, SAEKI Y, OHSHIMA S et al.: Transfer of rheumatoid arthritis into severe combined immunodeficient mice. The pathogenetic implications of T cell populations oligoclonally expanding in the rheumatoid joints. J. Clin. Invest. (1995) 96(4):1746-1758.
90. LINSLEY PS, BRADY W, GROSMAIRE L, ARUFFO A, DAMLE NK, LEDBETTER JA: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. (1991) 173(3):721-730.
91. CARRENO BM, COLLINS M: The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Ann. Rev. Immunol. (2002) 20:29-53.
92. STUART RW, RACKE MK: Targeting T cell costimulation in autoimmune disease. Expert. Opin. Ther. Targets (2002) 6(3):275-289.
93. SCHWARTZ RH: T cell anergy. Ann. Rev. Immunol. (2003) 21:305-334.
94. LINSLEY PS, BRADY W, URNES M, GROSMAIRE LS, DAMLE NK, LEDBETTER JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. (1991) 174(3):561-569.
95. WALUNAS TL, BAKKER CY, BLUESTONE JA: CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. (1996) 183(6):2541-2550.
96. KREMER JM, DOUGADOS M, EMERY P et al.: Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. (2005) 52(8):2263-2271.
97. GENOVESE MC, BECKER JC, SCHIFF M et al.: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor or inhibition. N. Engl. J. Med. (2005) 353(11):1114-1123.
98. BEYERSDORF N, GAUPP S, BALBACH K et al.: Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J. Exp. Med. (2005) 202(3):445-455.
99. HOPKINS M: Can super-antibody drugs be tamed? Nature (2006) 440:855-856.
100. +. Int. Immunol. (1998) 10(6):775-783.
101. + T cells in rheumatoid arthritis. J. Immunol. (2005) 174(11):7292-7301.
102. MOWAT AM, STROBEL S, DRUMMOND HE, FERGUSON A: Immunological responses to fed protein antigens in mice. I. Reversal of oral tolerance to ovalbumin by cyclophosphamide. Immunology (1982) 45(1):105-113.
103. FRIEDMAN A, WEINER HL: Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc. Natl. Acad. Sci. USA (1994) 91(14):6688-6692.
104. + T cells in animal model of collagen-induced arthritis by oral administration of type II collagen. Arthritis Res. Ther. (2004) 6(3):R213-R219.
105. THOMPSON HS, STAINES NA: Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats. Clin. Exp. Immunol. (1986) 64(3):581-586.
106. ZHANG ZY, MICHAEL JG: Orally inducible immune unresponsiveness is abrogated by IFN-γ treatment. J. Immunol. (1990) 144(11):4163-4165.
107. BARNETT ML, KREMER JM, ST CLAIR EW et al.: Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. (1998) 41 (2):290-297.
108. TRENTHAM DE, DYNESIUS-TRENTHAM RA, ORAV EJ et al.: Effects of oral administration of type II collagen on rheumatoid arthritis. Science (1993) 261(5129):1727-1730.
109. McKOWNKM, CARBONE LD, KAPLAN SB et al.: Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum. (1999) 42(6):1204-1208
110. CHOY EH, SCOTT DL, KINGSLEY GH et al.: Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum. (2001) 44(9):1993-1997.
111. MYERS LK, HIGGINS GC, FINKEL TH et al.: Juvenile arthritis and autoimmunity to type II collagen. Arthritis Rheum. (2001) 44(8):1775-1781.
112. ZANDBELT M, HOUBIERS J, VAN DEN HOOGEN F et al.: Intranasal administration of recombinant human cartilage glycoprotein 39: a Phase I trial in rheumatoid arthritis patients. Am. Coll. Rheumatol. (2006) (Abstract 286).
113. KAVANAUGH A, GENOVESE M, BAUGHMAN J et al.: Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled Phase I trial. J. Rheumatol. (2003) 30(3):449-454.
114. BRUNSBERG U, GUSTAFSSON K, JANSSON L et al.: Expression of a transgenic class II Ab gene confers susceptibility to collagen-induced arthritis. Eur. J. Immunol. (1994) 24(7):1698-1702.
115. MICHAELSSON E, ANDERSSON M, ENGSTROM A, HOLMDAHL R: Identification of an immunodominant type-II collagen peptide recognized by T cells in H-2q mice: self tolerance at the level of determinant selection. Eur. J. Immunol. (1992) 22(7):1819-1825.
116. ROSLONIEC EF, BRAND DD, MYERS LK et al. Induction of autoimmune arthritis in HLA-DR4 (DRB1*0401) transgenic mice by immunization with human and bovine type II collagen. J. Immunol. (1998) 160(6):2573-2578.
117. DZHAMBAZOV B, NANDAKUMAR KS, KIHLBERG J, FUGGER L, HOLMDAHL R, VESTBERG M: Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules. J. Immunol. (2006) 176(3):1525-1533.
118. VAN EDEN W, KOETS A, VAN KOOTEN P, PRAKKEN B, VAN DER ZR: Immunopotentiating hear shock proteins: negotiators between innate danger and control of autoimmunity. Vaccine (2003) 21(9-10):897-901.
119. ANDERTON SM, VAN DER ZR, PRAKKEN B, NOORDZIJ A, VAN EDEN W. Activation of T cells recognizing self 60-kD heat shock protein can protect against experimental arthritis. J. Exp. Med. (1995) 181(3):943-952.
120. DURAI M, GUPTA RS, MOUDGIL KD: The T cells specific for the carboxyl-terminal determinants of self (rat) heat-shock protein 65 escape tolerance induction and are involved in regulation of autoimmune arthritis. J. Immunol. (2004) 172(5):2795-2802.
121. VAN EDEN W, THOLE JE, VAN DER ZR et al.: Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis. Nature (1988) 331(6152):171-173.
122. RAGNO S, COLSTON MJ, LOWRIE DB, WINROW VR, BLAKE DR, TASCON R: Protection of rats from adjuvant arthritis by immunization with naked DNA encoding for mycobacterial heat shock protein 65. Arthritis Rheum. (1997) 40(2):277-283.
123. HAQUE MA, YOSHINO S, INADA S, NOMAGUCHI H, TOKUNAGA O, KOHASHI O: Suppression of adjuvant arthritis in rats by induction of oral tolerance to mycobacterial 65-kDa heat shock protein. Eur. J. Immunol. (1996) 26(11):2650-2656.
124. QUINTANA FJ, CARMI P, MOR F, COHEN IR: Inhibition of adjuvant-induced arthritis by DNA vaccination with the 70-kd or the 90-kd human heat-shock protein: immune cross-regulation with the 60-kd heat-shock protein. Arthritis Rheum. (2004) 50(11):3712-3720.
125. QUINTANA FJ, CARMI P, MOR F, COHEN IR: Inhibition of adjuvant arthritis by a DNA vaccine encoding human heat shock protein 60. J. Immunol. (2002) 169(6):3422-3428.
126. PRAKKEN AB,VANHOEIJ MJ,KUIS W et al.: T-cell reactivity to human HSP60 in oligo-articular juvenile chronic arthritis is associated with a favorable prognosis and the generation of regulatory cytokines in the inflamed joint. Immunol. Lett. (1997) 57(1-3):139-142.
127. DETANICO T, RODRIGUES L, SABRITTO AC et al.: Mycobacterial heat shock protein 70 induces interleukin-10 production: immunomodulation of synovial cell cytokine profile and dendritic cell maturation. Clin. Exp. Immunol. (2004) 135(2):336-342.
128. PRAKKEN BJ, SAMODAL R, LE TD et al.: Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA (2004) 101(12):4228-4233.
129. ALBANI S, TREMOULET A, GENOVESE M et al.: Phase II trial of epitope-specific immunotherapy in rheumatoid arthritis. Am. Coll. Rheumatol. (2005) (Abstract L5).
130. LI R, LI X, LI Z: Altered coflagen II peptides inhibited T-cell activation in rheumatoid arthritis. Clin. Immunol. (2006) 118(2-3):317-323.
131. JIMI E, GHOSH S: Role of nuclear factor-κB in the immune system and bone. Immunol. Rev. (2005) 208:80-87.
132. KARIN M: How NF-κB is activated: the role of the IκB kinase (IKK) complex. Oncogene (1999) 18(49):6867-6874.
133. KISHORE N, SOMMERS C, MATHIALAGAN S et al.: A selective IKK-2 inhibitor blocks NF-κB-dependent gene expression in interleukin-I β-stimulated synovial fibroblasts. J. Biol. Chem. (2003) 278(35):32861-32871.
134. MCINTYRE KW, SHUSTER DJ, GILLOOLY KM et al.: A highly selective inhibitor of IκB kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum. (2003) 48(9):2652-2659.
135. OKAZAKI Y, SAWADA T, NAGATANI K et al.: Effect of nuclear factor-κB inhibition on rheumatoid fibroblast-like synoviocytes and collagen induced arthritis. J. Rheumatol. (2005) 32(8):1440-1447.
136. PODOLIN PL, CALLAHAN JF, BOLOGNESE BJ et al.: Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IκB kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J. Pharmacol. Exp. Ther. (2005) 312(1):373-381.
137. 3 adenosine receptor agonists in murine autoimmune arthritis models. J. Rheumatol. (2005) 32(3):469-476.
138. 2 adenosine receptor agonist. Am. Coll. Rheumatol. (2006) (Abstract L7).
139. FEARNS C, KLINE L, GRAM H et al.: Coordinate activation of endogenous p38α, β, γ, and δελτα by inflammatory stimuli. J. Leukoc. Biol. (2000) 67(5):705-711.
140. FENG Y, SCHREINER GF, CHAKRAVARTY S, LIU DY, JOLY AH: Inhibition of the mitogen activated protein kinase, p38 α, prevents proinflammatory cytokine induction by human adherent mononuclear leukocytes in response to lipid loading. Atherosclerosis (2001) 158(2):331-338.
141. WESTRA J, LIMBURG PC, DE BOER P, VAN RIJSWIJK MH: Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts. Ann. Rheum. Dis. (2004) 63(11):1453-1459.
142. WEI YH, LI Y, QLANG CJ: Effects and mechanisms of FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor, on adjuvant arthritis in rats. Int. Immunopharmacol. (2004) 4(13):1625-1632.
143. BADGER AM, ROSHAK AK, COOK MN et al.: Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures. 0steoarthritis Cartilage (2000) 8(6):434-443.
144. LEE MR, DOMINGUEZ C: MAP kinase p38 inhibitors: clinical results and an intimate took at their interactions with p38α protein. Curr. Med. Chem. (2005) 12(25):2979-2994.
145. HADDAD JJ: VX-745. Vertex Pharmaceuticals. Curr. Opin. Investig. Drugs (2001) 2(8):1070-1076.
146. PETTIT AR, JI H, VON STECHOW D et al.: TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. (2001) 159(5):1689-1699.
147. REDLICH K, HAYER S, RICCI R et al.: Osteoclasts are essential for TNF-α-mediated joint destruction. J. Clin. Invest. (2002) 110(10):1419-1427.
148. LI J, SAROSI I, YAN XQ et al.: RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA (2000) 97(4):1566-1571.
149. SHALHOUB V, FAUST J, BOYLE WJ et al.: Osteoprotegerin and osteoproregerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. J. Cell Biochem. (1999) 72(2):251-261.
150. VANDERBORGHT A, LINSEN L, THEWISSEN M, GEUSENS P, RAUS J, STINISSEN P: Osteoprotegerin and receptor activator of nuclear factor-ΚB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls. J. Rheumatol. (2004) 31(8):1483-1490.
151. PETTIT AR, WALSH NC, MANNING C, GOLDRING SR, GRAVALLESE EM: RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology (2006) 45:1068-1076.
152. GREGOREK H, IMIELSKA D, GORNICKI J, MIKOLAJEWICZ J, PRZERADZKA B, MADALINSKI K: Development of IgG subclasses in healthy Polish children. Arch. Immunol. Ther. Exp. (1994) 42(5-6):377-382.
153. + T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma. Ann. Surg. Oncol. (2004) 11(10):892-899.
154. EHRENSTEIN MR, EVANS JG, SINGH A et al.: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J. Exp. Med. (2004) 200(3):277-285.
155. SHOU J, BULL CM, LI L et al.: Identification of blood biomarkers of rheumatoid arthritis by transcript profiling of peripheral blood mononuclear cells from the rat collagen-induced arthritis model. Arthritis Res. Ther. (2006) 8(1):R,28.
156. RAZA K, FALCIANI F, CURNOW SJ et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res. Ther. (2005) 7(4):R784-R795.